TP53 and cancer: p73, the homologue of the tumour suppressor p53, exists as two major forms: the full-length TAp73 form and the amino-terminally truncated, transactivation domain-deficient (DN)-p73 form.1 While DNp73 has been shown to be overexpressed in cancers and lead to resistance to cell death by virtue of its ability to inhibit both p53 and TAp73-dependent apoptosis2–5, TAp73’s role in carcinogenesis is more complex.